This latest PYC announcement has grabbed my interest. Back in...

This latest PYC announcement has grabbed my interest. Back in February's Investor update, PYC indicated that they were 'live' and working on a 2nd generation of their platform technology. The general tenor of their overall presentation was quite upbeat, however the excitement clearly jumped significantly when this topic came up. Check it out...from about the 50 minute mark and onwards.

Recent industry developments provide us, (PYC), to test and potentially demonstrate with greater certainty patient outcomes before we even start dosing patients via 'disease in a dish' capability that utilizes stem cells, (from targeted patients), and develop 'mini eyes' and 'mini brains'.

It was signalled that PYC was likely to report further on this matter, Q2 2023, (which theoretically means sometime very soon).

This above seems to corollate with Tides poster presentation. (Commencing this coming Sunday)

IMO we could be getting quite close to an inflection point where we may be able to substantially de-risk RP11, (and more), and if so ,that could be a catalyst to some sort of 'BD' potential on the horizon..

Key Highlights of the Tides poster presentations include:
• The potency outperformance of PYC’s bi-functional RNA therapeutics over the
equivalent ‘naked’ RNA therapy in vivo;

• The safety and tolerability profile of PYC’s modality for the treatment of retinal
diseases in Good Laboratory Practice toxicology studies;

• The durability of PYC’s modality in vivo and how this informs a preferred patient
dosing profile in clinical studies; and

• The disease-modifying potential of PYC’s Retinitis Pigmentosa type 11 (RP11)
and Autosomal Dominant Optic Atrophy (ADOA) programs including data:

Demonstrating modulation of expression of the genes involved in these
respective indications; and

The restoration of the functional consequences downstream of gene
insufficiency, in models derived from patients with RP11 and ADOA after administration of PYC’s
investigational drug candidates.